Counterfeiting

Combating Counterfeits

The pharma industry is working toward establishing the ideal anticounterfeiting system, combining authentication tools and track-and-trace capabilities to serialize at the unit level, for every drug.

By Marie Redding
Freelance Writer

It’s increasingly difficult—even for the experts—to tell the difference between a counterfeit drug and the real thing. Consumers feel they have no sure way of knowing if they’re getting duped. They may even ingest a harmful ingredient a counterfeiter has used to make a fake pill—like highway paint, floor wax, and boric acid—according to a CBS news report.

No votes yet

Tech Beats Security Breach

There is a growing need for creative out-of-the-box technologies that prevent a rift in patient safety while keeping a company’s investments and reputation in good standing. Counterfeiting, diversion, the resale of expired products, and complexities within the supply chain are forcing the healthcare industry to seek ahead-of-the-curve security packaging.

No votes yet

United Front Forms Against Counterfeits

A cooperative agreement between the U.S. Food and Drug Administration and the World Health Organization aims to construct a sound evidence base on counterfeit, falsified, and substandard medicines. The recent project proposal was developed by WHO in response to a call for a proposal on counterfeit medicines from FDA, but the two organizations will work closely together on the project.

No votes yet

NanoGuardian Bolsters Defenses Against Counterfeiting and Illegal Diversion

As evidence of its continued commitment to the fight against counterfeiting and illegal diversion, NanoGuardian forges ahead with several business moves in 2010. Among some of the most prominent efforts are a global collaboration with Capsugel, the extension of NanoEncryption technology to cover single-use vial caps and pre-filled syringes, and a partnership agreement with Altegrity Risk. NanoGuardian, a division of NanoInk, delivers brand protection solutions to defend against illegal diversion and counterfeiting.

Can FDA Cure Two Ills with Just One Bill?

Senator Michael Bennet, D-CO, has had enough of drug recalls. This week Bennet introduced Senate Bill S. 3690, the Drug Safety and Accountability Act of 2010, to increase FDA's authority over drug quality and safety.

No votes yet

FDA Updates Warning To Providers On Counterfeit Surgical Mesh

Washington, DC. June 10 -- The Health Forum issued the following news release: The Food and Drug Administration today alerted hospitals and others not to use certain surgical mesh products that have been identified as counterfeit and are not sterile, although labeled as so. The counterfeit mesh, which has been recalled, may increase the risk of infection if implanted in a patient and may not meet other specifications of the authentic product, the FDA said. The mesh is labeled with the C.R. Bard/Davol brand name, but was not made by Bard.

Covectra Offers Solutions to Secure Drug Supply Chain

Covectra (Southborough, MA) announces the availability of technology solutions to support pharmaceutical companies in quickly responding to an FDA guideline issued last week, which relates to regulatory standards in developing a secure pharmaceutical supply chain.

 

Counterfeit Surgical Mesh Found

FDA has issued a warning to healthcare providers about counterfeit surgical mesh being distributed in the United States under the C. R. Bard/Davol brand name. To date, investigations have identified four product sizes as counterfeit flat sheet polypropylene surgical mesh:

Covectra’s SmartPhone Technology To Combat Counterfeiting

Covectra (Southborough, MA) is offering a new multi-layered approach to anti-counterfeiting and diversion control to a variety of industries, including pharmaceuticals, luxury goods, automotive, electronics, and premium beverages. Covectra has made available its new smartphone technology application, Brand Loyalty and Integrity Services (BLIS). The application provides data analysis features that can be used by manufacturers and brand owners to provide increased security, monitor consumer purchase patterns, and provide brand promotional opportunities.

Drug Reimportation Carries Risk of Counterfeits, PhRMA Says

The Pharmaceutical Research and Manufacturers of America (PhRMA) spoke out against drug reimportation today, citing the worldwide counterfeit threat. The comments appear to come in response to those healthcare reformists seeking legalization of such importation.

“It is critical that we maintain our focus on comprehensive health reform to help all Americans access high-quality and affordable healthcare coverage and services," said PhRMA senior vice president Ken Johnson. "The Congress should not pursue policies that could expose Americans to counterfeit and substandard drug products and potentially weaken the Food and Drug Administration (FDA) and the Department of Homeland Security (DHS) by crippling their ability to fulfill their mission in protecting public health and safety. The worldwide counterfeit threat is knocking at America’s door and will soon be greeted if prescription drug importation proposals move forward."

Syndicate content